

Research and Reviews: Journal of Pharmacology and Toxicological Studies

A Short Note on Alcohol Withdrawal Syndrome

Venkateswarlu N*

Vagdevi Institute of Pharmacy, Nellore, Andhra Pradesh, India

Review Article

Received: 29/08/2016
Accepted: 31/08/2016
Published: 13/09/2016

*For Correspondence

Venkateswarlu N, Department of Pharmaceutics, Vagdevi Institute of Pharmacy, Nellore.

E-mail:
nussum.venkatesh@gmail.com.

Keywords: Alcohol withdrawal syndrome, Seizures, Benzodiazepines, alcohol

ABSTRACT

Alcohol withdrawal syndrome is the word for the indications that happen after a heavy drinker unexpectedly ends or considerably decreases their alcohol consumption. With Alcohol withdrawal syndrome, you may experience a mixture of physical and expressive symptoms, from mild nervousness and fatigue to nausea. Specific symptoms of Alcohol withdrawal syndrome are as severe as hallucinations and seizures. Alcohol withdrawal syndrome can be life-threatening.

INTRODUCTION

Alcohol withdrawal syndrome [1-9] is a set of indications that can happen when an individual decreases or ends alcohol drinking after extended times of usage. Continued and extreme usage of liquor leads to tolerance and physical dependency. The withdrawal syndrome is mainly a hyper-excitability reaction of the central nervous system due to absence of alcohol [10-15]. Usual indications of withdrawal consist of anxiety, delirium tremens (DTs), and seizures. Sedative-hypnotics, such as alcohol, are well recognized for their capacity to cause physical dependency. This dependency is due to alcohol-induced neuro-adaptation. Withdrawal is categorized by neuropsychiatric excitability and autonomic instabilities. Dependence on further sedative-hypnotics [16-20] can rise the severity of the withdrawal syndrome. About half of individuals with alcoholism will improve withdrawal signs upon reducing their usage.

SYMPTOMS AND SIGNS

Signs and indications of alcohol withdrawal happen mainly in the central nervous system [21-28]. The severity of withdrawal can differ from minor symptoms such as sleep instabilities and nervousness to severe and life-threatening indications such as delirium, hallucinations, and autonomic unpredictability.

The severity of indications is read out by sum of factors, the utmost significant of which is degree of alcohol intake, distance of time the single has been consuming alcohol [29-36], and earlier history of alcohol withdrawal. Indications are also collected and classified:

Delirium Tremens

Hyper adrenergic state, confusion, tremors, diaphoresis, impaired attention/consciousness, and visual and auditory hallucinations. This generally occurs 1-3 days after alcohol end. Delirium tremens is the utmost severe form of withdrawal and happens in 5 to 20% of patients feeling detoxification and 30% of patients feeling withdrawal seizures [37-39].

Alcohol Hallucinosis

Patients have transient visual, auditory, or tactile hallucinations, but are otherwise clear [39-41].

Withdrawal Seizures

seizures happen in 48 hours of alcohol cessations and happen either as a single comprehensive tonic-clonic seizure or as a short-lived occurrence of numerous seizures [42-48].

Progression

Typically the severity of the signs experienced will depend on the quantity and period of earlier alcohol intake, as well as the amount and severity of previous withdrawals. Even the utmost severe of these signs can happen in as slight as 2 hours later cessation; so, the general unpredictability requires either pre-planned hospitalization, treatment corresponding with a physician, or at the very smallest fast access to medical care; and a supportive system of friends or family should be announced earlier to addressing detoxification [49-53]. In several cases, though, indications follow a rationally expected time frame as exemplified beneath:

Six to 12 hours later the consumption of the last drink, withdrawal symptoms such as shivering, headache, sweating, nervousness, vomiting occur. Additional similar indications may also be in this era. Twelve to 24 hours later cessation, the condition may progress to such main signs as confusion, hallucinations, tremor, anxiety, and similar illnesses [54-62].

At 1-2 days subsequent the last ethanol consumption, the chance of seizures must be expected. Meanwhile, none of the previous withdrawal symptoms will have decreased. Seizures convey the danger of death for the alcoholic [63-65].

Although most frequently, the patient's state begins to increase previous the 48-hour mark, it can sometimes stay to increase in severity to delirium tremens, categorized by hallucinations that are indistinguishable from truth, severe confusion, seizures, high blood pressure and fever which can continue wherever from 4 to 12 days [66-68].

Protracted Withdrawal

An extended alcohol withdrawal syndrome happens in various alcoholics wherever withdrawal symptoms keep on the far side the severe withdrawal stage however repeatedly at an acute level of strength and bit by bit dropping with severity over time. This disorder is additionally sometimes expressed to because the post-acute-withdrawal syndrome [69-71]. Various withdrawal indications will keep for a minimum of a year later withdrawal of alcohol. Symptoms will comprise a yearning for alcohol, incapability to feel want from commonly gratifying things, evaporation of sensorium, disorientation, nausea and headache. Wakefulness is additionally a standard prolonged symptom that continues once the acute withdrawal section of alcohol [72-76]. Wakefulness has conjointly been found to impact relapse rate. Studies have found that metal or nontricyclic will support treat the uninterrupted symptom of sleep disorder in up alcoholics. Sleep disorder are often problematic to treat in alcoholics due to the many ancient sleep aids effort via a GABAA receptor mechanism and are cross tolerant with alcohol. Though, nontricyclic isn't cross tolerant with alcohol. The acute stage of the alcohol withdrawal syndrome can even sometimes be extended. Long psychosis has been expressed within the medical works as a probable however uncommon feature of alcohol withdrawal [77-81].

PATHOPHYSIOLOGY

Chronic usage of alcohol results in variations in brain chemistry significantly within the GABAergic system [82-86]. Various variations happen appreciate fluctuations in organic phenomenon and down regulation of GABAA receptors. Throughout acute alcohol withdrawal, variations additionally occur appreciate up regulation of alpha4 comprising GABAA receptors and down regulation of alpha1 and alpha3 having GABAA receptors. Organic compound variations happening throughout alcohol withdrawal are belittled with medications that square measure used for acute detoxification. With abstinence from alcohol and cross tolerant medication these alterations in neurochemistry increasingly come to traditional. Diversifications to the NMDA system additionally happen as an impact of repetitive alcohol intoxication and square measure concerned within the hyper-excitability of the CNS throughout the alcohol withdrawal syndrome. Homocysteine levels that square measure raised throughout chronic consumption increase even more throughout the withdrawal stage and should result in excito-neurotoxicity [87-89]. Changes in ECG, in specific a rise in QT interval, and electroencephalogram irregularities together with could happen throughout early withdrawal. Dysfunction of the hypothalamic-pituitary-adrenal axis and improve discharge of corticotropin-releasing internal secretion happen throughout each acute yet as long abstinence from alcohol and present to each acute and long withdrawal symptoms. Anhedonia/dysphoria symptoms, which may continue as a part of a long withdrawal could also be because of Intropin underneath activity [90-95].

Diagnosis

Numerous clinics use the Clinical Institute Withdrawal Assessment for Alcohol (CIWA) procedure so as to live the extent of withdrawal gift and consequently the quantity medication needed. Once overdoing of alcohol is suspected however consumption history is unclear, analysis for raised values of carbohydrate-deficient globulin or gammaglutamyl enzyme will facilitate build the analysis of alcohol overdoing and dependency additional clear. The CIWA has equally been reduced (currently named the CIWA-Ar), whereas tenacious its validity and irresponsibleness, to support assess patients additional professionally because of the intense nature of alcohol withdrawal [96-99].

Treatment

Benzodiazepines square measure effective for the management of symptoms yet because the interference of seizures. Bound vitamins are a vital a part of the management of alcohol withdrawal syndrome [100]. In those with severe symptoms inmate care is usually needed. In those with lesser symptoms treatment reception could also be doable with daily visits with a health care supplier.

Benzodiazepines

Benzodiazepines square measure the foremost oft used medication for the treatment of alcohol withdrawal and square measure typically safe and active in destroying indications of alcohol withdrawal. These categories of medicines square measure commonly active in symptoms management however ought to be used reasonably. Although benzodiazepines have an extended history of effectively treating and stopping withdrawal, there's no accord on the perfect one to use. The foremost oft used agents square measure long benzodiazepines, appreciate Librium and benzodiazepine. This square measure alleged to be superior to alternative benzodiazepines for treating delirium and allow for extended periods between medicating. Though, benzodiazepines with intermediate half-lives like benzodiazepine could also be harmless in people with liver complications [88,96,99].

The main discussion among usage of long benzodiazepines and short-acting is that of simple usage. Longer-acting medication, appreciate benzodiazepine, is medicated fairly often. However, indication will happen that "symptom-triggered regimens" appreciate those used once treating with benzodiazepine, square measure as harmless and active, however reduced action periods and medication quantity have used.

Though benzodiazepines square measure terribly effective at treating alcohol withdrawal, they ought to be rigorously used. Benzodiazepines ought to solely be used for short periods in alcoholics WHO aren't already passionate about on them, as they share cross tolerance with alcohol. Here could be a risk of subbing alcohol dependence with sedative drug dependence or adding another addiction. Also, disturbed amino acid sedative drug receptor perform is an element of alcohol dependence and chronic benzodiazepines could stop full recovery from alcohol elicited mental effects. the mix of benzodiazepines and alcohol will intensify the contrary psychological effects of every alternative manufacturing improved depressive effects on mood and rise dangerous actions and square measure typically contraindicated excluding for alcohol withdrawal [87,100].

Vitamins

The prophylactic management of anti-beriberi factor, folacin and vitamin B6 intravenously is usually recommended before beginning any super molecule comprising fluids or food. Alcoholics area unit of lacking in various nutrients which might cause severe issues throughout alcohol withdrawal love the event of Wernicke syndrome. The vitamins of most significance in alcohol withdrawal area unit anti-beriberi factor and vitamin M. to assist to prevent Wernicke syndrome alcoholics should be managed a vitamin pill preparation with enough quantities of ant beriberi factor and vitamin M. Vitamins should be managed before any aldohexose is run then Wernicke syndrome are often triggered. These vitamins area unit of combined into banana bag that is given intravenously to patients [98].

Anticonvulsants

Certain indication specifies that topiramate, carbamazepine, and different anticonvulsants area unit active within the management of alcohol withdrawal; but, investigation is partial. A Cochrane review equally declared that the indication to support the role of anticonvulsants over benzodiazepines within the treatment of alcohol withdrawal isn't necessary and noted weaknesses within the studies on the market. The Cochrane review did note, however, that aldehyde combined with sedative drug conferred advantage over Librium with value more highly to grievous facet effects and additionally noted that carbamazepine might have advantages sure indications [77].

Prevention of additional drinking

There are unit 3 medicines wont to facilitate stop reappearance to consumption: medicine, naltrexone, and acamprosate. They're used afterwards withdrawal went on.

Other

Clonidine is also employed in combination with benzodiazepines to assist a number of the symptoms.

There's inadequate proof to support the employment of baclofen for alcohol withdrawal syndrome. Antipsychotics, a neuroleptic drug, are typically employed in addition to benzodiazepines to regulate agitation or psychopathy. Antipsychotics might doubtless worsen alcohol withdrawal as they lower the seizure threshold. Clozapine, olanzapine, or low-potency phenothiazines (such as chlorpromazine) are significantly risky; if used, extreme caution is needed. Whereas blood vessel ethyl alcohol might on paper be used, proof to support this use, a minimum of in those that are terribly sick, is inadequate [86-92].

Prognosis

Failure to attain the alcohol withdrawal syndrome befittingly will cause permanent brain injury or death. It's been planned that brain injury thanks to alcohol withdrawal is also stopped by the management of NMDA antagonists, Ca antagonists, and endocrine antagonists [91-95].

Substances impairing recovery

Continuous use of benzodiazepines might injure recovery from bodily process and psychological feature impairments from alcohol. Roll of tobacco smoking might abate or delay with restitution of brain methods in rising alcoholics.

REFERENCES

1. Crosier BS and Marsch LA. Harnessing Social Media for Substance Use Research and Treatment. *J Alcohol Drug Depend*; 2016;4:238.
2. Song SNJ and Yoshizaki K. Mechanism and Clinical Significance of IL-6 Combined with TNF- α or IL-1 for the Induction of Acute Phase Proteins SAA and CRP in Chronic Inflammatory Diseases. *J Alcohol Drug Depend*; 2016;4:239.
3. Khaleel HA, et al. Alcohol Sale Status and Suicide in Kentucky, 2005-2012. *J Alcohol Drug Depend*; 2016;4:240.
4. Razvodovsky YE. The Effect of Gorbachev's Anti-alcohol Campaign on Road Traffic Accidents Mortality in Belarus. *J Alcohol Drug Depend*; 2016;4:241.
5. Barbaro M and Locatelli M. The Markers for Alcohol Abuse: The Good, the Bad and the Ugly. *J Alcohol Drug Depend*. 2016;4:242.
6. Hiranita T. Identification of the Sigma-2 Receptor: Distinct From the Progesterone Receptor Membrane Component 1 (PGRMC1). *J Alcohol Drug Depend*. 2016;4:e130.
7. Mizuo K, et al. Acute Ethanol Administration Increases Mir-124 Expression via Histone Acetylation in the Brain. *J Alcohol Drug Depend*. 2016;4:232.
8. Clark A, et al. Parent-Adolescent Interactions and Substance Use: A Prospective, Observational Study of Mexican-Origin Families. *J Alcohol Drug Depend*. 2016;4:233.
9. Shushpanova TV, et al. Original Anticonvulsant Urea Derivative Alters the Properties of Benzodiazepine Receptors "Central" and "Peripheral" Types in the Cerebral Cortex of "Heavy Drinkers" Rats. *J Alcohol Drug Depend*. 2016;4:234.
10. Ito H. Intermediate to Long-Term Results of Periacetabular Osteotomy in Patients Younger and Older Than 40 Years of Age. *J Alcohol Drug Depend*. 2016;4:235.
11. Zago P, et al. Alcohol Use Disorder and Inflammatory Cytokines in a Population Sample of Young Adults. *J Alcohol Drug Depend*. 2016;4:236.
12. Montalto M. How Have Academic Theories of Domestic Violence Influenced Western Physical Domestic Violence Treatment Programs in Recent Years? *J Alcohol Drug Depend*. 2016;4:237.

13. Hiranita T. (-)-Trans- Δ^9 -Tetrahydrocannabinol-Like Discriminative-Stimulus Effects of Gabapentin in Cannabis Users. *J Alcohol Drug Depend.* 2016;4:e129.
14. Ito H. Sex-Dependent Differences in Acetabular Dysplasia Characteristics. *J Alcohol Drug Depend.* 2016;4:229.
15. Dunlap E. Knowledge, Awareness and Behavior: HIV/AIDS and Disasters. *J Alcohol Drug Depend.* 2016;4:230.
16. Groß C, et al. Adolescents Admitted to In-Patient Treatment with Alcohol Intoxication: Risk and Resilience Factors Associated with Problematic Alcohol Use. *J Alcohol Drug Depend.* 2016;4:231.
17. Hiranita T. Self-Administration of JWH-018 A Synthetic Cannabinoid in Experimentally Naïve Rats . *J Alcohol Drug Depend.* 2015;3:e128.
18. Dembo R, et al. Sexual Risk Behavior among Male and Female Truant Youths: Exploratory, Multi-Group Latent Class Analysis. *J Alcohol Drug Depend.* 2015;3:226.
19. Sordi AO, et al. Childhood Trauma and Resilience: Vulnerabilities to Develop Crack/Cocaine Dependence. *J Alcohol Drug Depend.* 2015;3:227.
20. Montalto M. Alcoholics Anonymous: One Treatment Program to Rule Them All?. *J Alcohol Drug Depend.* 2015;3:228.
21. Hiranita T. Cocaine Antagonists; Studies on Cocaine Self-Administration. *J Alcohol Drug Depend.* 2015;3:e125.
22. Hiranita T. Self-Administration of an Endogenous Cannabinoid 2-Arachidonoylglycerol in Experimentally Naïve Rats. *J Alcohol Drug Depend.* 2015;3:e126.
23. Hiranita T. Preclinical Efficacy of Novel Vesicular Monoamine Transporter 2 Inhibitors as Antagonists of d-Methamphetamine Self-Administration in Rats. *J Alcohol Drug Depend.* 2015;3:e127.
24. Spas JJ and Weyandt L. Alcohol and Its Effect on Adolescent Brain Development and Executive Functioning: Some Results from Neuroimaging. *J Alcohol Drug Depend.* 2015;3:220.
25. Ge Y and Liu J. Psychometric Analysis on Neurotransmitter Deficiency of Internet Addicted Urban Left-behind Children. *J Alcohol Drug Depend.* 2015;3:221.
26. Horton A. Violence and Illicit Drug Use in America: The Mass Incarceration of African American Males. *J Alcohol Drug Depend.* 2015;3:222.
27. Reper P. Diagnosis of Coma through Social Media Announcement. *J Alcohol Drug Depend.* 2015;3:223.
28. Cheadle JE, et al. Teen Alcohol Use and Social Networks: The Contributions of Friend Influence and Friendship Selection. *J Alcohol Drug Depend.* 2015;3:224.
29. Essam Hafez M, et al. Parenchymatous Toxicity of Tramadol: Histopathological and Biochemical Study. *J Alcohol Drug Depend.* 2015;3:225.
30. Adermark L. Astrocyte Function in Alcohol Reward and Addiction. *J Alcohol Drug Depend.* 2015;3:e123.
31. Hiranita T and Collins GT. Differential Roles for Dopamine D1-Like and D2-Like Receptors in Mediating the Reinforcing Effects of Cocaine: Convergent Evidence from Pharmacological and Genetic Studies. *J Alcohol Drug Depend.* 2015;3:e124.
32. Talpins KS, et al. The Miami-Dade Protocol: Making Drugged Driving Enforcement a Reality. *J Alcohol Drug Depend.* 2015;3:212.
33. Coßmann JC and Bonnet U. Screening for Misuse of Approved Antidementives in the Elderly Non-Demented Hospital Population. *J Alcohol Drug Depend.* 2015;3:213.

34. Ceccanti M, et al. Serum BDNF and NGF Modulation by Olive Polyphenols in Alcoholics during Withdrawal. *J Alcohol Drug Depend.* 2015;3:214.
35. Razvodovsky YE. Alcoholic Psychoses in Russia and Belarus: A Comparative Analysis of Trends. *J Alcohol Drug Depend.* 2015;3:215.
36. Dahlman D, et al. Attitudes towards Hepatitis C and Treatment Willingness in Injection Drug Users: A Follow-up Interview Study. *J Alcohol Drug Depend.* 2015;3:217.
37. Poncin M, et al. Sensitivity for Self-Discrepancy Predicts Alcohol Consumption in Alcohol- Dependent Inpatients with High Self-Consciousness. *J Alcohol Drug Depend.* 2015;3:218.
38. Chevalley P, et al. Value of Visual Screening by Medical Doctors in Diagnosing Alcohol Abuse: A Prospective Study. *J Alcohol Drug Depend.* 2015;3:219.
39. Hiranita T. Medications Discovery: Importance of Assessment of Drug Self Administration Dose-Effect Curves. *J Alcohol Drug Depend.* 2015;3:e121.
40. Hiranita T. Trace Amine-Associated Receptor Type 1 as A Target for The Development of Treatments for Stimulant Abuse. *J Alcohol Drug Depend.* 2015;3:e122.
41. Aslam N. Horrendous Situation of Substance Abuse in Pakistan: A Bird's Eye View on Socio-Demographics. *J Alcohol Drug Depend.* 2015;3:201.
42. Yawson AE, et al. Sociodemographic and Socioeconomic Correlates of Alcohol Use among Older Adults in Ghana. *J Alcohol Drug Depend.* 2015;3:202.
43. Holleran Steiker LK, et al. Transforming Austin: Augmenting the System of Care for Adolescents in Recovery from Substance Use Disorders. *J Alcohol Drug Depend.* 2015;3:203.
44. MSN SKK. The Importance of Oral Health in Treatment Outcomes for the Chemically Dependent Population. *J Alcohol Drug Depend.* 2015;3:204.
45. George B. Efficacy of Acceptance and Mindful Based Relapse Prevention Program on Emotion Regulation Difficulty among Alcoholics in Kerala India. *J Alcohol Drug Depend.* 2015;3:205.
46. Asmaro D, et al. Behavioral and Electrophysiological Responses to Tobacco-Related Words in a Smoking Stroop Task Discriminate between Relapse or Abstinence following a One-Month Quit Attempt. *J Alcohol Drug Depend* 3:206.
47. Basu D and Ghosh A. Profile of Patients with Dual Diagnosis: Experience from an Integrated Dual Diagnosis Clinic in North India. *J Alcohol Drug Depend.* 2015;3:206.
48. Zenebe Y, et al. (2015) Alcohol Use Disorders and Its Associated Factors among Psychiatric Outpatients in Jimma University Specialized Hospital, Southwest Ethiopia. *J Alcohol Drug Depend.* 2015;3:208.
49. Becker A, et al. Electrical Stimulation of the Nucleus Accumbens Shell Reduces Voluntary Ethanol Consumption in Bulbectomized Rats. *J Alcohol Drug Depend.* 2015;3:210.
50. Ragab AR, et al. Endogenous Ethanol Production Levels in Saudi Arabia Residents. *J Alcohol Drug Depend.* 2015;3:211.
51. Hiranita T. In Vivo Significance of In Vitro Studies on G-Protein- Coupled Receptor Heteromers. *J Alcohol Drug Depend.* 2015;3:e120.
52. Aslam N. Drug Addiction, Criminality and Birth Order. *J Alcohol Drug Depend.* 2015;3:191.
53. Kaithuru PN and Stephen A. Alcoholism and its Impact on Work Force: A Case of Kenya Meteorological Station, Nairobi. *J Alcohol Drug Depend.* 2015;3:192.

54. Macdonald S, et al. Factors Related to Simultaneous Cocaine and Alcohol Use for Clients in Treatment. *J Alcohol Drug Depend.* 2015;3:193.
55. Devin A, et al. Investigating Autobiographical Memory Impairments in Chronic Heavy Cannabis Users: Methodology and Hypotheses. *J Alcohol Drug Depend.* 2015;3:194.
56. Razvodovsky YE. Fraction of Tuberculosis Mortality Attributable to Alcohol in Russia. *J Alcohol Drug Depend.* 2015;3:195.
57. Allan J, et al. Illicit Fentanyl use in Rural Australia – An Exploratory Study. *J Alcohol Drug Depend.* 2015;3:196.
58. Yoshioka-Maxwell A, et al. Methamphetamine Use among Homeless Former Foster Youth: The Mediating Role of Social Networks. *J Alcohol Drug Depend.* 2015;3:197.
59. Bonnet U and Scherbaum N. Striking Similarities between Clinical and Biological Properties of Ketamine and Ethanol: Linking Antidepressant-After Effect and Burgeoning Addiction?. *J Alcohol Drug Depend.* 2015;3:198.
60. Cacabelos R. Impact of Genomic Medicine on the Future of Neuropsychopharmacology. *J Neuropsychopharmacol Mental Health.* 2015;1:e101.
61. Patrono E. Epigenetic Mechanisms on Food Addiction. *J Neuropsychopharmacol Mental Health.* 2015;1:e102.
62. Vignoli T, et al. Neurobiological Evidence in Alcohol Addiction Can Help Pharmacological Treatment Personalization. *J Neuropsychopharmacol Mental Health.* 2015;1:e103.
63. Duko B, et al. Prevalence and Correlates of Co-occurring Substance Use Disorder among Patients with Severe Mental Disorder at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia. *J Neuropsychopharmacol Mental Health.* 2015;1:101.
64. Cashin A, et al. Psychiatric and Mental Health Core Capabilities and Learning Outcomes Developed in Nurse Practitioner Programmes in Australia and the United States of America. *J Neuropsychopharmacol Mental Health.* 2015;1:102.
65. Logotheti M, et al. Gene Expression Analysis of Fibroblasts from Patients with Bipolar Disorder. *J Neuropsychopharmacol Mental Health.* 2015;1:103.
66. Ray P and Khess CRJ. Level of Insulin Resistance in Schizophrenia Patients and Its Association with Treatment with Antipsychotics. *J Neuropsychopharmacol Mental Health.* 2016;1:104.
67. Del Barrio AG, et al. Hyponatremia and Chewing Gum in a Patient with Anorexia Nervosa. *J Neuropsychopharmacol Mental Health.* 2016;1:105.
68. Bastons-Compta A, et al. Foetal Alcohol Spectrum Disorder (FASD) Diagnostic Guidelines: A Neuropsychological Diagnostic Criteria Review Proposal. *J Neuropsychopharmacol Mental Health.* 2016;1:e104.
69. Belbin O. Thinking Non-Linearly. *J Neuropsychopharmacol Mental Health.* 2016;1:105.
70. De Berardis D. Second Generation Long-acting Injectable Antipsychotics as a First-line Treatment of First Episode Schizophrenia: “Lights” and “Shadows”. *J Neuropsychopharmacol Mental Health.* 2016;1:e106.
71. Bayard M, et al. Alcohol withdrawal syndrome. *American family physician.* 2004;15:69.
72. Yost DA. Alcohol withdrawal syndrome. *American family physician.* 1996;54:657-664.
73. Carlson RW, et al. Alcohol withdrawal syndrome. *Critical care clinics.* 2012;28:549-585.
74. Withdrawal A. Alcohol Withdrawal Syndrome.

75. Gallimberti L, et al. Gamma-hydroxybutyric acid for treatment of alcohol withdrawal syndrome. *The Lancet*. 1989;334:787-789.
76. Freund G. Alcohol withdrawal syndrome in mice. *Archives of neurology*. 1969;21:315-320.
77. Claassen CA and Adinoff B. Alcohol withdrawal syndrome. *CNS drugs*. 1999;12:279-291.
78. Hayashida M, et al. Comparative effectiveness and costs of inpatient and outpatient detoxification of patients with mild-to-moderate alcohol withdrawal syndrome. *New England Journal of Medicine*. 1989;320:358-365.
79. Sullivan JT, et al. Assessment of alcohol withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar). *British journal of addiction*. 1989;84:1353-1357.
80. Scullard T. Alcohol Withdrawal Syndrome. *Canadian Journal of Critical Care Nursing*. 2016;27.
81. Addolorato G, et al. Rapid suppression of alcohol withdrawal syndrome by baclofen. *The American journal of medicine*. 2002;112:226-229.
82. Roelofs SM. Hyperventilation, anxiety, craving for alcohol: a subacute alcohol withdrawal syndrome. *Alcohol*. 1985;2:501-505.
83. Hall W and Zador D. The alcohol withdrawal syndrome. *The Lancet*. 1997;349:1897-1900.
84. Gross MM, et al. Acute alcohol withdrawal syndrome. In *The biology of alcoholism* 1974;191-263.
85. Gillman MA and Lichtigfeld FJ. Alcohol withdrawal syndrome. *The Lancet*. 1997;350:737.
86. Addolorato G, et al. Baclofen in the treatment of alcohol withdrawal syndrome: a comparative study vs diazepam. *The American journal of medicine*. 2006;119:276-313.
87. Taub J and Beresford TP. Alcohol withdrawal syndrome. *Alcohol abuse and liver disease*. 2015:155-163.
88. McKeon A, et al. The alcohol withdrawal syndrome. *Journal of Neurology, Neurosurgery & Psychiatry*. 2008;79:854-862.
89. Baumgartner GR and Rowen RC. Clonidine vs chlordiazepoxide in the management of acute alcohol withdrawal syndrome. *Archives of Internal Medicine*. 1987;147:1223-1226.
90. Landers DF. Alcohol withdrawal syndrome. *American family physician*. 1983;27:114-118.
91. Pierog S, et al. Withdrawal symptoms in infants with the fetal alcohol syndrome. *The Journal of pediatrics*. 1977;90:630-633.
92. Vale A. Alcohol withdrawal syndrome. *The Foundation Years*. 2008;4:55-58.
93. Hanks KC and Paguntalan J. Alcohol Withdrawal Syndrome.
94. Powell AH and Minick MP. Alcohol withdrawal syndrome. *AJN The American Journal of Nursing*. 1988;88:312-315.
95. Wetterling T, et al. A new rating scale for the assessment of the alcohol-withdrawal syndrome (AWS scale). *Alcohol and Alcoholism*. 1997;32:753-760.
96. Bonnet U, et al. Treatment of alcohol withdrawal syndrome with gabapentin. *Pharmacopsychiatry*. 1999;32:107-109.
97. Spies CD, et al. Therapy of alcohol withdrawal syndrome in intensive care unit patients following trauma: results of a prospective, randomized trial. *Critical care medicine*. 1996;24:414-422.
98. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. *Jama*. 1997;278:144-151.
99. Ritola E and Malinen L. A double-blind comparison of carbamazepine and clomethiazole in the treatment of alcohol withdrawal syndrome. *Acta Psychiatrica Scandinavica*. 1981;64:254-259.

100. Monte-Secades R, Rabuñal-Rey R, et al. Inpatient alcohol withdrawal syndrome. *Revista Clínica Española* (English Edition). 2015;215:107-116.